Disease heterogeneity in amyotrophic lateral sclerosis poses a substantial challenge in drug
development. Categorization based on clinical features alone can help us predict the …

Biomarkers in amyotrophic lateral sclerosis: a review of new... : Current Opinion in
Neurology Biomarkers in amyotrophic lateral sclerosis: a review of new developments …

Biomarkers for amyotrophic lateral sclerosis : Current Opinion in Neurology Biomarkers for
amyotrophic lateral sclerosis : Current Opinion in Neurology Log in or Register Subscribe to …

Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across
a range of platforms. Replication of results, however, has been absent in all but a few cases …

Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disease that affects
upper (UMN) and lower motor (LMN) neurons. It is associated with a short survival and there …

Amyotrophic lateral sclerosis (ALS) is a fatal condition primarily characterized by the
selective loss of upper and lower motor neurons. At present, the diagnosis and monitoring of …

Neurophysiological biomarkers in amyotrophic lateral scleros... : Current Opinion in
Neurology Neurophysiological biomarkers in amyotrophic lateral sclerosis : Current Opinion …

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease,
and only modest disease-modifying strategies have been established to date. Numerous …

Amyotrophic lateral sclerosis (ALS; motor neuron disease) is a relentlessly progressive
disorder. After half a century of trials, only one drug with modest disease-modifying potency …

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that mainly
causes degeneration of the upper and lower motor neurons, ultimately leading to paralysis …